Goldman Sachs’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $327M | Sell |
4,671,950
-1,931,747
| -29% | -$99.9M | 0.03% | 558 |
|
|
2026
Q1 | $335M | Buy |
6,603,697
+2,653,078
| +67% | +$124M | 0.04% | 466 |
|
|
2025
Q4 | $117M | Buy |
3,950,619
+770,870
| +24% | +$20.9M | 0.01% | 901 |
|
|
2025
Q3 | $82.1M | Sell |
3,179,749
-223,490
| -7% | -$6.23M | 0.01% | 1073 |
|
|
2025
Q2 | $93.9M | Buy |
3,403,239
+188,143
| +6% | +$4.95M | 0.01% | 919 |
|
|
2025
Q1 | $91.1M | Sell |
3,215,096
-86,639
| -3% | -$3.07M | 0.01% | 829 |
|
|
2024
Q4 | $137M | Sell |
3,301,735
-76,113
| -2% | -$3.64M | 0.02% | 654 |
|
|
2024
Q3 | $226M | Sell |
3,377,848
-807,710
| -19% | -$74.2M | 0.04% | 473 |
|
|
2024
Q2 | $497M | Buy |
4,185,558
+255,646
| +7% | +$32.4M | 0.08% | 226 |
|
|
2024
Q1 | $419M | Sell |
3,929,912
-621,714
| -14% | -$62.7M | 0.07% | 271 |
|
|
2023
Q4 | $453M | Buy |
4,551,626
+447,639
| +11% | +$37.6M | 0.08% | 235 |
|
|
2023
Q3 | $424M | Buy |
4,103,987
+632,350
| +18% | +$70.5M | 0.09% | 209 |
|
|
2023
Q2 | $422M | Buy |
3,471,637
+412,412
| +13% | +$55M | 0.09% | 204 |
|
|
2023
Q1 | $470M | Buy |
3,059,225
+306,053
| +11% | +$50.5M | 0.11% | 184 |
|
|
2022
Q4 | $495M | Buy |
2,753,172
+1,490,684
| +118% | +$244M | 0.12% | 157 |
|
|
2022
Q3 | $149M | Sell |
1,262,488
-1,506,938
| -54% | -$229M | 0.04% | 502 |
|
|
2022
Q2 | $396M | Buy |
2,769,426
+1,156,961
| +72% | +$165M | 0.1% | 160 |
|
|
2022
Q1 | $278M | Buy |
1,612,465
+313,877
| +24% | +$52.8M | 0.06% | 325 |
|
|
2021
Q4 | $330M | Sell |
1,298,588
-286,235
| -18% | -$83.7M | 0.07% | 298 |
|
|
2021
Q3 | $610M | Buy |
1,584,823
+122,665
| +8% | +$45.2M | 0.13% | 139 |
|
|
2021
Q2 | $344M | Buy |
1,462,158
+406,484
| +39% | +$72.6M | 0.08% | 242 |
|
|
2021
Q1 | $138M | Sell |
1,055,674
-103,374
| -9% | -$15M | 0.03% | 496 |
|
|
2020
Q4 | $121M | Sell |
1,159,048
-659,317
| -36% | -$66.7M | 0.03% | 524 |
|
|
2020
Q3 | $129M | Sell |
1,818,365
-788,858
| -30% | -$55M | 0.04% | 471 |
|
|
2020
Q2 | $167M | Buy |
2,607,223
+1,089,796
| +72% | +$59.7M | 0.05% | 367 |
|
|
2020
Q1 | $45.4M | Buy |
1,517,427
+197,363
| +15% | +$4.54M | 0.02% | 936 |
|
|
2019
Q4 | $25.8M | Buy |
1,320,064
+91,314
| +7% | +$1.62M | 0.01% | 1642 |
|
|
2019
Q3 | $19.6M | Buy |
1,228,750
+101,293
| +9% | +$1.5M | 0.01% | 1798 |
|
|
2019
Q2 | $16.5M | Sell |
1,127,457
-42,988
| -4% | -$923K | ﹤0.01% | 1998 |
|
|
2019
Q1 | $23.8M | Sell |
1,170,445
-185,481
| -14% | -$3.44M | 0.01% | 1729 |
|
|
2018
Q4 | $20.7M | Buy |
+1,355,926
| New | +$22.3M | 0.01% | 1783 |
|
Other funds holding MRNA
TP
Goldman Sachs's MRNA Position: Q2 2026 in Review
Goldman Sachs reduced its Moderna (MRNA) stake by 29% in Q2 2026, selling an estimated $99.9M and leaving 4,671,950 shares worth $327M. The position accounts for 0.03% of the portfolio, ranked #558.
Goldman Sachs first reported a position in MRNA in Q4 2018 and has held it in 31 quarters since. The position peaked at $610M in Q3 2021. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.
- Goldman Sachs held 4,671,950 shares of Moderna worth $327M as of Q2 2026.
- Goldman Sachs sold 1,931,747 Moderna shares in Q2 2026, an estimated $99.9M.
- Moderna made up 0.03% of Goldman Sachs's portfolio in Q2 2026, its #558 holding.
- Goldman Sachs first reported a position in Moderna in Q4 2018 and has held it in 31 quarters since.
- Goldman Sachs's Moderna position peaked at $610M in Q3 2021.
- 780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.